Research & Clinical Trials
Penn's Abramson Cancer Center, a National Cancer Institute-designated comprehensive cancer center, oversees one of the largest clinical trial programs in the country, with more than 200 trials available at any one time. Part of the Abramson Cancer Center, the Penn Center for Myeloproliferative Neoplasms allows access to clinical trials with novel agents designed specifically for patients with MPN.
Current MPN Clinical Trials
- Study of Combination Ruxolitinib and Decitabine Treatment for Accelerated Phase MPN or Post-MPN AML(NCT02076191)
- Efficacy and safety of Midostaurin Administered in Aggressive Systemic Mastocytosis or Mast Cell Leukemia +/- an Associated Hematological Clonal Non-Mast Cell Lineage Disease (NCT00782067) study ongoing but not recruiting participants
- Controlled MyeloFibrosis Study With ORal JAK Inhibitor Treatment: The COMFORT-I Trial (NCT00952289) study ongoing but not recruiting participants
- MPD-RC Research Tissue Bank (NCT00666549)
Penn Stem Cell and Xenograft Core (SCXC) is a comprehensive resource laboratory that integrates a viable tissue bank of normal human hematopoietic cells and hematopoietic malignancies with a full range of xenograft services. The SCXC is committed to facilitating and promoting translational research involving primary human hematopoietic tissues, and boasts a large repository of samples from patients with myeloproliferative neoplasms. All samples are fully annotated and frozen as viable cells, with expert consultative services in primary human hematopoietic stem/progenitor and leukemic cell culture and manipulation is available.